Five cases of viral rebound on injectable treatment puzzle researchers
Long-acting injectable treatment with cabotegravir and rilpivirine did not result in a higher rate of viral rebound, a study in the Netherlands shows.
But looking at five cases of viral rebound in the Dutch cohort, investigators observed the development of high-level drug resistance to one or both injectable agents that could seriously limit future treatment options.
The findings were presented at the 19th European AIDS Conference (EACS 2023) in Warsaw.
Long-acting cabotegravir (Vocabria) and rilpivirine (Rekambys) is the first long-acting injectable treatment for HIV. It was approved in the European Union in 2020 for treatment of people with supressed viral load.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.